CA-ANDERSEN-GLOBAL
24.3.2021 11:02:09 CET | Business Wire | Pressemeddelelse
Andersen Global forener sin platform i Nordamerika, idet dets medlemsfirmaer i Canada antager brandet, "Andersen", hvilket afspejler organisationens evne til at levere en komplet pakke med integrerede tjenester gennem sine medlems- og samarbejdsfirmaer over hele verden.
De canadiske medlemsfirmaer, der tidligere drev virksomhed under navnet Andersen Tax, deler nu det fælles brand "Andersen" med det amerikanske medlemsfirma på regional basis, sammen med medlemsfirmaer over hele verden i Europa, Latinamerika, Mellemøsten og Afrika. Det amerikanske medlemsfirma skiftede til Andersen-brandet i 2019, hvilket startede den globale antagelse af navnet af organisationens medlemsfirmaer i 2020 og begyndelsen af 2021.
"Denne forening under et fælles brand demonstrerer vores fælles kultur, værdier og vores forpligtelse til at betjene vores kunder på en sømløs måde over hele verden," sagde bestyrelsesformand for Andersen Global og administrerende direktør for Andersen, Mark Vorsatz. "Dette er et vigtigt skridt i vores globale organisations udvikling, idet vi fortsætter med at udvide og styrke vores globale platform."
Grundlagt i 2002 af 23 tidligere skattepartnere fra Arthur Andersen, startede Andersen sin rejse som WTAS LLC, et selskab, der kun leverede skattetjenester, som etablerede WTAS Global i 2013. Det stiftende amerikanske medlemsfirma begyndte derefter at drive virksomhed som Andersen Tax i 2014, og den globale organisation blev kendt som Andersen Global. Den globale organisation trådte ind på det canadiske marked i 2016 og driver nu virksomhed med fem partnere og næsten 40 eksperter på kontorer i Montreal, Vancouver, Calgary og Edmonton.
"Vi mener, at dette er en milepæl, der styrker de værdier og visioner, der forbliver kernen i vores firma, både lokalt og globalt," sagde administrerende direktør hos Andersen i Montreal, Simon Davari. "Denne overgang understøtter vores vækst og udvikling, fremhæver bredden og dybden af vores ekspertise og styrker vores position på det canadiske marked."
Warren Dueck, administrerende direktør hos Andersen i Vancouver, tilføjede: "I løbet af de sidste par år er vores firma vokset markant, og dets udvikling fremhæver vores 'one firm'-kultur, da vi arbejder sømløst med at bygge videre på det eksisterende fundament for Andersen-brandet i Nordamerika sammen med vores kolleger i USA. Idet vi ser frem mod dette næste trin i vores firmas udvikling, forbliver vores team dedikeret til at levere uovertrufne tjenester til kunder, især hvad angår amerikanske og canadiske grænseoverskridende skattetjenester."
Andersen Global er en international sammenslutning af juridisk adskilte, uafhængige medlemsfirmaer bestående af skatte- og juraeksperter fra hele verden. Efter at være blevet etableret i 2013 af det amerikanske medlemsfirma Andersen Tax LLC har Andersen Global nu over 7.000 eksperter globalt og er repræsenteret på mere end 261 lokaliteter via sine medlems- og samarbejdsfirmaer.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210324005403/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum